RenovoRx Shares Up After a New 510(k) Clearance from FDA for its Proprietary RenovoCath Delivery System
RenovoRx, Inc. (NASDAQ: RNXT) shares spiked more than 25% Tuesday after the clinical-stage biopharmaceutical company announced that it has received a new 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its proprietary RenovoCath Delivery System. Targeted Therapy with...